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Immunotherapy is a fast advancing methodology involving one of two approaches: (1) com-
pounds targeting immune checkpoints and (2) cellular immunomodulators. The latter
approach is still largely experimental and features in vitro generated, live immune effector
cells, or antigen-presenting cells. γδT cells are known for their efficient in vitro tumor killing
activities. Consequently, many laboratories worldwide are currently testing the tumor killing
function of γδT cells in clinical trials. Reported benefits are modest; however, these studies
have demonstrated that large γδT-cell infusions were well tolerated. Here, we discuss the
potential of using human γδ T cells not as effector cells but as a novel cellular vaccine for
treatment of cancer patients. Antigen-presenting γδT cells do not require to home to tumor
tissues but, instead, need to interact with endogenous, tumor-specific αβ T cells in sec-
ondary lymphoid tissues. Newly mobilized effector αβT cells are then thought to overcome
the immune blockade by creating proinflammatory conditions fit for effector T-cell homing
to and killing of tumor cells. Immunotherapy may include tumor antigen-loaded γδ T cells
alone or in combination with immune checkpoint inhibitors.
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HUMAN BLOOD γδ T CELLS
Human blood γδ T cells constitute a minor subset (1–5%) of total
T cells that is characterized by their T-cell antigen receptors (TCR)
encoded by rearranged V-gamma and V-delta genes. Among blood
γδT cells, those expressing Vγ9Vδ2–TCR greatly outnumber other
γδ T-cell subsets whereas in peripheral tissues Vγ9Vδ2+ T cells
are relatively scarce. Their numbers are substantially increased
in blood of patients suffering from various infectious diseases,
indicating an involvement of Vγ9Vδ2+ T cells in antimicro-
bial immunity. Indeed, early work revealed that Vγ9Vδ2+ T
cells are selective for a microbial non-peptide metabolite, (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), found in
numerous commensal and pathogenic microbes, including bac-
teria, Plasmodium and Toxoplasma species but not in man (1,
2). The same type of γδ T cells also responds (albeit at >104-
fold higher concentrations) to the structurally related compound
isopentenyl pyrophosphate (IPP), a metabolite of the mevalonate
pathway in eukaryotes including man. Of interest, IPP was sug-
gested to be increased in stressed cells, such as tumor cells, and
its interaction with a specific IPP- (and HMBPP-) binding protein
(BTN3A/CD277) leads to Vγ9Vδ2+ T-cell activation (reviewed
by the groups of E. Adams, E. Scotet, and T. Hermann in this
Research Topic). IPP levels can be elevated artificially by addition
of amino-bisphosphonates (such as zoledronate; see below) that
inhibit an intracellular IPP-metabolizing enzyme. Consequently,
treatment of PBMC with zoledronate results in the selective activa-
tion and outgrowth of Vγ9Vδ2+ T cells. The exquisite selectivity
for HMBPP/IPP distinguishes Vγ9Vδ2+ T cells from αβ T cells
that recognize a myriad of short peptides under MHC restric-
tion. In fact, the Vγ9Vδ2–TCR endows a sizable army of blood γδ
T cells to become immediately mobilized in response to a single
class (“phosphoantigens”) of danger signals produced by microbes
and possibly tumor cells (3). Relevant to the discussion below, this
“mono-selectivity” allowed us to study the TCR-mediated func-
tionality and migration properties of the entire Vγ9Vδ2+ T-cell
population.
DISCOVERY OF γδT-APC: γδ T CELLS WITH
ANTIGEN-PRESENTATION FUNCTION
The myriad of effector and memory T cells present in our body
can be distinguished based on their functional and migratory pro-
files. In fact, the characteristic functions of individual T cells are
intimately related to their migratory properties, as exemplified by
the distinct chemokine receptor profiles decorating individual T
helper subsets (4, 5). For example, the chemokine receptor CXCR5
identifies follicular B helper T (TFH) cells that are specialized in
orchestrating T cell-dependent antibody responses within the fol-
licular compartments of secondary lymphoid tissues (6, 7). Our
research on human blood γδ T cells (Vγ9Vδ2-TCR+ γδ T cells)
began with the realization that treatment of γδ T cells with phos-
phoantigens induced the rapid and transient expression of CCR7
(8), the chemokine receptor enabling the rendezvous between
naïve/central memory T cells and mature DC within lymph nodes
(9). Immunological analyses revealed their presence in the T-cell
zone but also B-cell follicles, the latter location suggesting that
γδ T cells affect humoral responses. Indeed, and similar to TFH
cells, co-culture of γδ T cells with tonsillar B cells resulted in
massive production of antibodies (8). In support, another lab
identified CXCR5 on activated γδ T cells (10) and, recently, we
and others reported the expression of the IL-21 receptor, link-
ing follicular γδ T cells with TFH cells and their B-cell targets
(11, 12).
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CCR7 expression is also in line with the view that activated γδ
T cells team up with αβ T cells and/or DC in the T-cell compart-
ment of secondary lymphoid tissues. In fact, short-term (1–3 days)
activation of γδ T cells with the phosphoantigens IPP or HMBPP
resulted in de novo expression (or up-regulation) of cell surface
proteins normally associated with DC, including antigen presen-
tation (MHC class I and II), co-stimulatory (CD40, CD80, CD86),
and adhesion (CD11a, CD11b, CD11c, CD18, CD54) receptors.
This observation led to detailed investigations into the possi-
bility that activated (CCR7+) γδ T cells behaved like bona fide
antigen-presenting cells (APC). Indeed, short-term activated γδ
T cells were capable of processing simple (tetanus toxoid) and
complex (M. tuberculosis PPD) protein antigens and inducing
antigen-specific immune responses in primary, autologous αβ
T cells (13). Activated γδ T cells did this equally well as donor
matched monocyte-derived DC (moDC). Of note, short-term
activated αβ T cells failed to express DC markers and were unable
to present peptide antigens to αβ T cells, although under special
conditions cloned T-cell lines were reported to induce responses
in antigen-specific responder T-cell lines (14). Subsequent stud-
ies revealed that short-term activated γδ T cells were also capable
of antigen cross-presentation, a process describing the induction
of CD8+ αβ T-cell responses to extracellular antigens. The pre-
cise mechanisms underlying antigen cross-presentation require
further clarification, although it is generally assumed that extracel-
lular antigens need to overcome intracellular membrane barriers
in order to access the proteasome in the cytoplasm, which produces
the peptide substrates for loading onto nascent MHC class I mol-
ecules (15). This process is in clear contrast to the classical MHC I
pathway involving the processing of endogenous self- or microbe-
derived antigens. Obviously, CD8+ T cells-mediated killing of
tumor and infected cells depends on cross-presentation capa-
bilities of DC involved in processing corresponding cell debris.
Activated γδ T cells are excellent cross-presenting APC, as shown
by us (16, 17) and another laboratory (18). In fact, they seem to
be able to do so more consistently than donor matched moDC,
which may be explained by the reduced lysosomal activity in γδ
T cells (17). After all, being a subtype of phagocytes, DC are very
efficient in antigen uptake and intracellular degradation. Of note,
γδ T cells were shown to phagocytose opsonized particles (E. coli,
cell debris, microbeads), suggesting that phagocytosis, in addition
to macropinocytosis, can contribute to antigen processing in this
novel type of APC (18, 19). Induction of CD8+ T-cell responses
by peptide-pulsed γδ T cells was also demonstrated by another
group (20, 21). Finally, activated γδ T cells resemble professional
APC in their ability to trigger antigen-specific responses in naïve
(antigen inexperienced) T cells. In summary, all these findings
document unexpected properties that are normally associated DC
and prompted us to designate activated (but not freshly isolated,
resting) Vγ9Vδ2+ T cells as γδT-APC (1).
In the past, γδ T cells have been portrayed as uniquely situated
at the cross-road between innate and adaptive immunity, bridging
both worlds by means of expressing recombined TCR involved
in γδ T-cell activation and target cell lysis (hallmarks of adaptive
immunity) while at the same time recognizing non-peptide anti-
gens (phosphoantigens) in an MHC-unrestricted fashion similar
to pattern recognition receptors (hallmarks of innate cells) (22,
23). Our findings with γδT-APC add to this functional dichotomy,
although proof of APC functions under in vivo conditions is still
missing. Because γδ T cells respond to stress, e.g., elevated lev-
els of IPP in tumor cells and microbes harboring HMBPP, one
could envisage that the phosphoantigen-induced killing of target
cells by mobilized γδ T cells is accompanied by the processing
of tumor/microbial antigens and the subsequent induction of αβ
T-cell responses. Activated γδ T cells are known for their abun-
dant secretion of proinflammatory cytokines (TNFα, IFNγ) and,
accordingly, γδT-APC-mediated differentiation of CD4+ αβ T
cells resulted in effector cells dominated by a Th1-type cytokine
profile (13). It will be important to see if under appropriate co-
stimulatory conditions, γδT-APC are also capable of generating
alternative Th subsets. It is worth mentioning, however, that γδT-
APC are not equipped with the plethora of receptors sensing
environmental cues as DC and, thus, are unlikely to compete with
the numerous highly specialized DC whose inherent function it is
to control T-cell functions in all aspects of immunity (health and
disease). Instead, it appears that the APC function of γδ T cells is
limited to situations where they become activated by their TCR
ligands (phosphoantigens).
METHODS FOR THE GENERATION OF ANTIGEN-PRESENTING
γδT-APC
Autologous moDC have been widely used in clinical trials as cel-
lular vaccine with limited success. In fact, despite >10 years of
translational research, clinically approved, moDC-based therapies
still do not exist. Bottlenecks are manifold, including the dif-
ficulty of obtaining large numbers of moDC with robust APC
function. Our recent findings suggest that γδT-APC represent a
promising alternative to moDC. Many laboratories have already
demonstrated how easy it is to expand γδ T cells to very large
numbers during in vitro culture (24–35). Based on these find-
ings, we have developed a method for the generation of in vitro
expanded γδT-APC that may provide the basis for their large-
scale manufacture under clinical-grade conditions (36). In brief,
best results, both in terms of yield and quality, are achieved when
PBMC samples isolated from fresh blood are stimulated once with
zoledronate and then cultured in the presence of the growth factors
IL-2 and IL-15. Zoledronate is a bisphosphonate drug known for
its ability to increase intracellular IPP in target cells to levels suffi-
cient for the selective activation of Vγ9Vδ2+ γδ T cells (37). After
14 days of culture, γδTells have expanded >1000-fold and >800-
fold with PBMC of healthy individuals and melanoma patients,
respectively,yielding 10–50 millionγδT cells per milliliter of whole
blood. Day 14 γδ T cells retained their functionality as assessed
by cytokine secretion and proliferation in response to HMBPP.
Secreted cytokines included IFNγ and TNFα, which are typically
produced by primary γδ T cells in response to phosphoantigens,
as well as several inflammatory chemokines whereas immune
inhibitory cytokines (TGFβ, IL-10) were not detected. Day 14
γδ T cells also killed tumor cells during in vitro culture. Impor-
tantly, and similar to short-term activated γδ T cells, expanded
γδ T cells largely retained many cell surface receptors normally
associated with APC, including antigen presentation (MHC I and
II), co-stimulation (CD80, CD86), and adhesion (CD11a, CD54)
molecules. Some of these were further elevated or re-expressed
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transiently (CD40 and CCR7) in response to re-stimulation with
HMBPP. APC marker expression was in line with their function-
ality. Without need for re-stimulation, day 14 γδ T cells were able
to process simple (influenza M1) and complex (PPD) antigens
and to induce antigen-specific αβ T-cell responses in both cul-
tured responder cell lines and primary responder cells present
in unfractionated PBMC. Stimulation with HMBPP did not fur-
ther enhance their APC function although, as discussed earlier,
expanded γδ T cells still largely maintained their responsiveness
(proliferation, cytokine secretion) to phosphoantigens. In sum-
mary, the current state of our research documents the feasibility
of transforming peripheral blood γδ T cells into almost unlimited
numbers of antigen-presenting γδT-APC. We now need to inves-
tigate the ability of day 14 γδ T cells to process tumor antigens,
either in purified form or as tumor cell extracts. We believe that
these APC are able to do so since we have already shown that acti-
vated γδ T cells efficiently processed extracts of influenza-infected
epithelial cells and induced M1-specific αβ T-cell responses (17).
It is further possible that interaction of γδ T cells with tumor cells
not only leads to tumor cell killing but also to tumor antigen-
presenting γδT-APC able to induce αβ T-cell responses locally
(tumor tissue) or at distal sites (lymph nodes).
A PROTOCOL FOR A FIRST-IN-MAN CLINICAL TRIAL WITH
TUMOR ANTIGEN-PRESENTING γδT-APC
Current state of research supports the following protocol for a
first-in-man clinical trial with tumor antigen-presenting γδT-
APC (Figure 1). Preliminary data indicate anticoagulant-treated
whole blood survives a 24 h shipment period in that PBMC sam-
ples retain responsiveness to zoledronate and IL-1/IL-15; similarly,
we know that tumor antigen-loaded γδT-APC can be frozen for
storage and/or shipment to cancer clinics. Therefore, it appears
that cancer patients will not need to visit a centralized γδ T-cell
culture facility for donating blood samples and receiving γδ T
cell-based vaccine infusions. A simplified procedure of γδT-APC
handling and distribution will facilitate clinical trials involving
multiple centers. Following 2 weeks on in vitro culture as described
above, tumor antigen-loaded γδT-APC will be prepared by cultur-
ing expanded γδ T cells for 24 h in the presence of defined tumor
antigen(s) or tumor cell extracts. A personalized immunotherapy
protocol will involve the treatment autologous γδT-cell prepa-
rations with extracts from the patient’s own tumor cells. After
washing and reformulation, tumor antigen-loaded γδT-APC will
be divided into individual bolus samples and then frozen in liquid
nitrogen for shipment to corresponding cancer clinics. The frozen
tumor antigen-loaded γδT-APC samples will then be prepared
locally for i.v. infusion into cancer patients according to treatment
regimens that need to be defined during clinical trials. Ideally, a
single round of cell culture will provide enough tumor antigen-
loaded γδT-APC for carrying out the entire round of treatment,
which may follow a prime-boost protocol. Obviously, effective cell
doses need to be established before being able to apply arithmetic
for the generation of expanded γδ T cells. A small sample of tumor
antigen-loaded γδT-APC will be retained for quality control that
will include sterility, purity, and APC phenotype assessments. Fre-
quently, PBMC from cancer patients yield reduced numbers of
expanded γδ T cells or cell preparations containing large (>50%)
ClinicCell Culture
Facility
T Cell Expansion
(2 wks)
T-APC Manufacture
(24h)
Tumor An!gen Loading
Quality Control
Storage
& Shipment
Blood Transport
Zoledronate
T-APC Vaccineγδ
γ δ
γ δ
FIGURE 1 | Manufacture of tumor antigen-loaded γδT-APC for
immunotherapy. Venous blood samples from cancer patients are shipped
to the centralized γδT-APC manufacture facility. Isolated PBMC are
stimulated with single doses of zoledronate and expanded during in vitro
culture for 2 weeks in the presence of IL-2 and IL-15. Expanded γδT cells
are treated for 24 h with tumor antigen (purified proteins, cell extracts) or, in
cases of low purity, enriched by magnetic beads isolation prior to tumor
antigen treatment. After reformulation, the γδT-APC vaccine undergoes
quality control tests and is frozen for transport to the clinic. γδT-APC vaccine
infusions may be followed by i.v. injections of zoledronate in order to trigger
γδT-cell responses (cytokine secretion, lymph node homing).
numbers of non-γδ T cells (mostly αβ T cells and/or NK cells)
(36), suggesting that a single magnetic beads purification step
could improve the vaccine function of antigen-loaded γδT-APC.
Last but not least, outcome measures for the γδT-APC-based
vaccine treatment need to be defined but will include immuno-
logical parameters determined in blood samples taken at intervals
after each infusion step as well as clinical parameters (e.g., see
details in EMA document)1. The above treatment protocol may
be extended to include a single i.v. infusion of zoledronate 24 h
after administration of each γδT-APC vaccine infusion. We know
that expanded γδ T cells retain full functionality (36). Equally
important, γδ T cells in cancer patients who have received γδ T-
cell infusions and even endogenous γδ T cells of cancer patients
who did not receive γδ T-cell infusions were reported to respond
to i.v. injections with zoledronate (32, 33, 38–43). Zoledronate is a
safe medication that is frequently used to treat patients with bone
disorders (44). Therefore, zoledronate may induce proinflamma-
tory cytokine (TNFα, IFNγ) production and lymph node homing
receptor (CCR7) expression and, thus, enhance the vaccine effect
in infused γδT-APC.
It is important to emphasize that γδT-APC-based vaccines tar-
get the immune system in cancer patients and beneficial effects
could include tumor control through immediate mobilization
of endogenous, tumor-specific effector T cells, or establishing
1http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2009/09/WC500003875.pdf
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tumor immunosurveillance involving the generation of long-lived,
tumor-specific memory T cells (or a combination of both
processes). In this regard, the here described method involving
tumor antigen-loaded γδT-APC differs fundamentally from cur-
rent clinical trials exploiting the tumor killing properties of
expanded γδ T cells (24–35).
CONCLUDING REMARKS
Many questions remain, including the one related to the type of
patients selected for a first-in-man clinical trial. As mentioned
above, γδT-APC-based vaccines target the patients’ own immune
system, indicating that patients suffering from tumors with well
described immunogenicity profiles would benefit the most (45).
Of course, tumor-specific immunity is a subject of intensive inves-
tigations and numerous tumor antigens have been associated with
certain types of tumors. However, we are still far from under-
standing the complex adaptive immune processes involved in
steady-state tumor control (immunosurveillance) and in tumor
progression (disease). Perhaps, the most promising indication
relates to conditions with prominent involvement of inhibitory
immune cells (Treg cells, myeloid-derived suppressor cells), and
current success with immune checkpoint inhibitors [anti-CTLA-4
Abs (Ipilimumab), anti-PD-1 Abs (Nivolumab)] may point us in
the right direction (46). In fact, combination therapy with γδT-
APC-based vaccines and immune checkpoint inhibitors may even
result in synergistic outcomes, i.e., blockade of inhibitory immune
cells by immune checkpoint inhibitors may facilitate the stim-
ulatory effect of γδT-APC-based vaccines leading to enhanced
tumor-specific effector T-cell responses and long-lived immuno-
surveillance T-cell formation. T-cell responses against melanoma
are well described (47), suggesting that melanoma patients are
promising candidates for a first-in-man clinical trial with γδT-
APC-based vaccines although other cancers with less well studied
immunogenicity should not be excluded. We envisage that the
proposed γδT-APC-based immunotherapy will not be restricted
to a single type of cancer since the majority of human cancers are
considered to evoke T-cell responses (45).
At present, a single cellular vaccine product (sipuleucel-T)
showing limited clinical benefits for prostate cancer patients has
been approved by the FDA. Thus far, DC-based vaccines have
not developed beyond the experimental stage. We believe that
our proposed γδT-APC-based therapy combines several features,
including ease of manipulation and functional robustness that will
make it a serious contender in the race to the first successful vac-
cine for use in immunotherapy of patients suffering from a broad
range of cancers.
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